di-tert-butyl 2,2'-(2-bromo-5-(4-nitrophenyl)pentylazanediyl)diacetate | 1258945-71-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: di-tert-butyl 2,2'-(2-bromo-5-(4-nitrophenyl)pentylazanediyl)diacetate
• 英文别名: tert-butyl 2,2'-(2-bromo-5-(4-nitrophenyl)pentylazanediyl)diacetate；Tert-butyl 2-[[2-bromo-5-(4-nitrophenyl)pentyl]-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]acetate
• CAS: 1258945-71-9
• 化学式: C₂₃H₃₅BrN₂O₆
• 分子量: 515.445
• InChiKey: FEWVGFFVSFEXCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  32
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  di-tert-butyl 2,2'-(2-bromo-5-(4-nitrophenyl)pentylazanediyl)diacetate 在 silver perchlorate 、 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 24.17h， 生成 tert-butyl-2-[(1-{4,7-bis[2-(tert-butoxy)-2-oxoethyl]-1,4,7-triazonan-1-yl}-5-[4-(hydroxyl-nitro)phenyl]-pentan-2-yl)[2-(tert-butoxy)-2-oxoethyl]amino]acetate
  参考文献：
  名称：

  Synthesis and Preclinical Evaluation of Bifunctional Ligands for Improved Chelation Chemistry of ⁹⁰Y and ¹⁷⁷Lu for Targeted Radioimmunotherapy

  摘要：

  We report a practical and high-yield synthesis of a bimodal bifunctional ligand 3p-C-NETA-NCS containing the isothiocyanate group for conjugation to a tumor targeting antibody. 3p-C-NETA-NCS was conjugated to a tumor-targeting antibody, trastuzumab, and the corresponding 3p-C-NETA-trastuzumab conjugate was evaluated and compared to trastuzumab conjugates of the known bifunctional ligands C-DOTA, C-DTPA, and 3p-C-DEPA for radiolabeling kinetics with Y-90 and Lu-177. 3p-C-NETA-trastuzumab conjugate exhibited extremely rapid complexation kinetics with Y-90 and Lu-177. Y-90-3p-C-NETA-trastuzumab and Lu-177-3p-C-NETA-trastuzumab conjugates were stable in human serum for 2 weeks. A pilot biodistribution study was conducted to evaluate in vivo stability and tumor targeting of Lu-177-radiolabeled trastuzumab conjugate using nude mice bearing ZR-75-1 human breast cancer. Lu-177-3p-C-NETA-trastuzumab conjugate displayed low radioactivity level at blood (1.6%), low organ uptake (<2.2%), and high tumor-to-blood ratio (6.4) at 120 h. 3p-C-NETA possesses favorable in vitro and in vivo profiles and is an excellent bifunctional chelator that can be used for targeted RIT applications using Y-90 and Lu-177 and has the potential to replace DOTA and DTPA analogues in current clinical use.

  DOI：

  10.1021/bc200696b
• 作为产物：
  描述：

  {tert-butoxycarbonylmethyl-[1-hydroxymethyl-4-(4-nitrophenyl)butyl]amino}acetic acid tert-butyl ester 在 N-溴代丁二酰亚胺(NBS) 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 以66%的产率得到di-tert-butyl 2,2'-(2-bromo-5-(4-nitrophenyl)pentylazanediyl)diacetate
  参考文献：
  名称：

  A highly effective bifunctional ligand for radioimmunotherapy applications

  摘要：

  一种新型的双功能配体（3p-C-NETA）用于抗体靶向的90Y和177Lu放射免疫治疗，通过特定位置的环氧乙烷离子环开合反应高效合成。

  DOI：

  10.1039/c0cc05707j

文献信息

• Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
  申请人：Chong Hyun-soon

  公开号：US09115094B2

  公开（公告）日：2015-08-25

  Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid and 1,4,7,10-tetraazacyclcododecane-N,N′,N″,N′″-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.

  用带有氨基或羟基的1,4,7-三氮杂环壬烷-N,N′,N″-三乙酸和1,4,7,10-四氮杂环十二烷-N,N′,N″,N′″-四乙酸化合物替代，以及它们的金属配合物、组合物、制备方法以及在诊断成像和治疗细胞疾病中的应用。
• A highly effective bifunctional ligand for radioimmunotherapy applications
  作者：Hyun-Soon Chong、Hyun A. Song、Chi Soo Kang、Thien Le、Xiang Sun、Mamta Dadwal、Hyunbeom Lee、Xiaoli Lan、Yunwei Chen、Anzhi Dai

  DOI：10.1039/c0cc05707j

  日期：——

  A novel bifunctional ligand (3p-C-NETA) for antibody-targeted radioimmunotherapy of 90Y and 177Lu was efficiently synthesized via regiospecific ring opening of an aziridinium ion.

  一种新型的双功能配体（3p-C-NETA）用于抗体靶向的90Y和177Lu放射免疫治疗，通过特定位置的环氧乙烷离子环开合反应高效合成。
• Efficient Bifunctional Decadentate Ligand 3p-<i>C</i>-DEPA for Targeted α-Radioimmunotherapy Applications
  作者：Hyun A Song、Chi Soo Kang、Kwamena E. Baidoo、Diane E. Milenic、Yunwei Chen、Anzhi Dai、M. W. Brechbiel、Hyun-Soon Chong

  DOI：10.1021/bc100586y

  日期：2011.6.15

  A new bifunctional ligand 3p-C-DEPA was synthesized and evaluated for use in targeted alpha-radioimmunotherapy. 3p-C-DEPA was efficiently prepared via regiospecific ring opening of an aziridinium ion and conjugated with trastuzumab. The 3p-C-DEPA-trastuzumab conjugate was extremely rapid in binding Bi-205/6, and the corresponding Bi-205/6-3p-C-DEPA-trastuzumab complex was stable in human serum. Biodistribution studies were performed to evaluate in vivo stability and tumor targeting of Bi-205/6-3p-C-DEPA-trastuzumab conjugate in tumor bearing athymic mice. Bi-205/6-3p-C-DEPA-trastuzumab conjugate displayed excellent in vivo stability and targeting as evidenced by low organ uptake and high tumor uptake. The results of the in vitro and in vivo studies indicate that 3p-C-DEPA is a promising chelator for radioimmunotherapy of Bi-212 and Bi-213.
• US9115094B2
  申请人：——

  公开号：US9115094B2

  公开（公告）日：2015-08-25
• Synthesis and Preclinical Evaluation of Bifunctional Ligands for Improved Chelation Chemistry of ⁹⁰Y and ¹⁷⁷Lu for Targeted Radioimmunotherapy
  作者：Chi Soo Kang、Xiang Sun、Fang Jia、Hyun A Song、Yunwei Chen、Michael Lewis、Hyun-Soon Chong

  DOI：10.1021/bc200696b

  日期：2012.9.19

  We report a practical and high-yield synthesis of a bimodal bifunctional ligand 3p-C-NETA-NCS containing the isothiocyanate group for conjugation to a tumor targeting antibody. 3p-C-NETA-NCS was conjugated to a tumor-targeting antibody, trastuzumab, and the corresponding 3p-C-NETA-trastuzumab conjugate was evaluated and compared to trastuzumab conjugates of the known bifunctional ligands C-DOTA, C-DTPA, and 3p-C-DEPA for radiolabeling kinetics with Y-90 and Lu-177. 3p-C-NETA-trastuzumab conjugate exhibited extremely rapid complexation kinetics with Y-90 and Lu-177. Y-90-3p-C-NETA-trastuzumab and Lu-177-3p-C-NETA-trastuzumab conjugates were stable in human serum for 2 weeks. A pilot biodistribution study was conducted to evaluate in vivo stability and tumor targeting of Lu-177-radiolabeled trastuzumab conjugate using nude mice bearing ZR-75-1 human breast cancer. Lu-177-3p-C-NETA-trastuzumab conjugate displayed low radioactivity level at blood (1.6%), low organ uptake (<2.2%), and high tumor-to-blood ratio (6.4) at 120 h. 3p-C-NETA possesses favorable in vitro and in vivo profiles and is an excellent bifunctional chelator that can be used for targeted RIT applications using Y-90 and Lu-177 and has the potential to replace DOTA and DTPA analogues in current clinical use.